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Abstract 
The authors analyzed a new clinical staging system and its correlation with pathologic 
findings and patient survival. Patients were eligible for inclusion in this longitudinal 
retrospective cohort study if they had cutaneous squamous cell carcinoma on the head or 
neck, underwent surgery and had a minimum 3 year follow-up. The primary study variable 
was using a new clinical staging system. Secondary variables included the parotid as a 
predictor of metastatic spread to the lymphatic nodes in the neck and primary lesion 
histopathologic traits. The outcome variable was patient survival. Associations between 
variables were assessed using Fisher’s exact test, Mann-Whitney test, Kaplan-Meier method 
and Mantel log-rank test. P<0.05 was considered significant. The sample was composed of 
103 patients. Regional metastatic disease was found in 24 patients. Histopathological analysis 
showed a higher frequency of neck metastatic disease if the parotid was positive for 
metastases (p=0.022). An extended staging system showed significant correlation between 
survival rate and substages (p=0.0105). Perineural invasion was a negative prognostic factor 
(p=0.0151) The results of this study suggest that combining curative parotidectomy and 
elective neck dissection could be beneficial in high risk patients. Both neck and parotid 
metastases should be included in the clinical and histological N classification. 
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Introduction 
Cutaneous squamous cell carcinoma (CSCC) comprises nearly 20% of all non-melanoma 
malignant skin tumors and represents a significant global health issue. Most lesions (80-90%) 
occur in sun-exposed regions of the head and neck.1,2 Although early stage cure rates are 
excellent, in some patients (5-10%) regional metastatic disease develops, lowering the 
survival rate by 50%.3 The rate of distant metastatic disease remains low, even in those 
patients with regional metastases.3,4 The inability to identify high risk lesions at the time of 
initial treatment is further aggravated by a lack of consensus on the appropriate management 
of regional metastases. Adequate surgical excision of the primary CSCC and an immediate 
curative lymphadenectomy remain essential in achieving control over disease progression and 
patient survival. There is no consensus on the indications for an elective neck dissection and 
extent of surgery, while further benefit can be expected from sentinel lymph node biopsy, 
selective neck dissection in high risk patients and adjuvant radiotherapy.5,6,7 Only limited data 
exist on the relationship between clinical staging of advanced regional disease and patient 
survival rate.8,9,10,11,12 The parotid gland is the first site for metastatic spread of head and neck 
CSCC, and parotid involvement poses a significant diagnostic and therapeutic challenge.1,13,14 
Therefore it is important to examine the relationship between patterns of metastatic spread in 
the parotid and the neck when planning surgical treatment. 
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Materials and Methods 
This retrospective longitudinal cohort study and its protocol were approved by the University 
of Zagreb Medical School Bioethics Board, adhering to the Helsinki Declaration of 1983. All 
patients with head and neck CSCC who were surgically treated from September 1st, 1983 to 
October 31st, 2007 were eligible for inclusion in a comprehensive oncological database (tum-
2). Patients were eligible for inclusion if they had a histopathologically confirmed CSCC on 
the head or neck, if they underwent primary surgical treatment in our institution, if the 
primary tumor measured >2 cm in its highest diameter and if they had a follow-up of 
minimum 3 years. The patients underwent extensive examinations and were treated according 
to standard clinical practices approved by a multidisciplinary oncological team. Clinical 
staging was carried out according to the current AJC staging system, but was revised using a 
new staging system (O’Brien’s PN classification) shown in Table 1, which separates patients 
into groups according to the extent of parotid disease and presence or absence of clinical neck 
disease.1,10,12 The patients were included consecutively, and follow-up lasted for a minimum 
of 3 years, until May 1st, 2010 or patient’s death. Demographic information, prior history of 
skin malignancy, location, lesion size, previous therapy, surgical procedure and reconstruction 
method details, histopathologic findings (margin status, number of positive lymph nodes, 
number of examined lymph nodes, extracapsular spread and/or perineural invasion) and 
evidence of regional metastatic disease was collected. Histologic margins were defined as 
“clear” if there was a definitive healthy tissue margin of >5 mm around the cancer tissue, 
while “near” margins were defined with <5 mm of healthy tissue. Patients with a “near” or 
“positive” margin were evaluated by a multidisciplinary oncology team and underwent re-
excision if necessary. The total number of surgically excised CSCC was well over a thousand 
patients, but due to strict study protocol criteria, the following patients were not eligible: 
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patients with primary tumors <2 cm in the highest diameter, incomplete documentation, 
incomplete follow-up or day clinic patients, or localization of CSCC on the lip, which is 
known to have clinical and histological characteristics and a poorer prognosis than other head 
and neck CSCC.15 Patterns of metastatic involvement of cervical nodes were analyzed and 
correlated with primary lesion localizations. These primary lesions were divided into 5 
different anatomic sublocalizations; 1. frontonasal, 2. auriculotemporal, 3. mental, submental 
and submandibular, 4. orbitozygomatic, 5. buccal and preauricular region (Figure 1). 
Localizations of regional metastatic disease were divided into the following anatomic regions: 
the parotid gland and neck regions I-VI, according to the recommendations proposed by the 
American Head and Neck Society and the American Academy of Otolaryngology-Head and 
Neck Surgery.16  
Statistical analysis was performed using MedCalc software (Version 11.2.1 © 1993-2010. 
MedCalc Software bvba Software, Broekstraat 52, 9030 Mariakerke, Belgium), using 
standard descriptive statistics and frequency tabulation as indicated. The data for the n=24 
cohort were expressed as ratios due to n<100. Associations between variables were assessed 
using Fisher’s exact test, Mann-Whitney test and Kaplan-Meier method with Mantel log-rank 
test applied to endpoints to establish survival or recurrence probabilities. All tests of statistical 
significance were performed using a two-sided 5% type I error rate.17 
6 
 
Results 
This study included 103 surgically treated patients from September 1st, 1983 to October 31st, 
2007, while maintaining strict exclusion criteria. Among the patients that were eligible for 
inclusion, 56 were women and 47 were men. Average age was 74.5 years (69 in men and 79 
in women) while ages ranged from 47 to 92 years. The highest incidence of head and neck 
CSCC was in the age group of 80-98 years, followed by the age group of 70-79 years. The 
average age of primary lesion occurrence was significantly greater in women (p<0.0012). Out 
of the 103 patients, a cohort of 24 patients with clinically apparent regional metastatic disease 
and neck dissection was formed. Data from the total cohort population (n=103) shows that the 
most frequent localization of the primary lesion was in the buccal and preauricular 
sublocalization (56,3%), followed by the frontonasal sublocalization (29,12%). Incomplete 
excision rate was 6.7%, and there was a significant positive statistical correlation with higher 
T stage in the cohort with regional metastatic disease (p=0.0018). Average lesion size ranged 
from 2.1 to 13.5 cm, with a median of 4.3 cm (n=103). There were 26 recurrences of the 
primary lesion both in the primary and metastatic disease localizations (25,2%), of which 15 
patients with primary localization recurrence, 5 with recurring regional neck disease, 1 patient 
with recurring parotid disease after parotidectomy and 5 patients with new primary lesions in 
the follow up interval.  Perineural invasion was recorded in 5 patients, while 2 patients had 
vascular invasion, all in the patient cohort with regional metastatic disease (n=24). Three 
patients with extensive primary lesions (8.1, 11.3 and 13,5 cm in diameter) were not 
submitted to skull base procedures upon review by a multidisciplinary oncological team. 
Regional metastatic disease rate was 23.3% (24/103) and the patients were singled out to form 
a separate cohort group. This group comprised of 12 men and 12 women with the highest 
incidence of CSCC in the 70-79 age group. The most common localization of primary lesions 
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was the auriculotemporal area (9/24), followed by the buccal and preauricular area (6/24). 
There were 10 patients with clinical N1 stage and 8 with clinical metastatic disease in the 
parotid gland only. There were 6 patients with clinical N2 stage. All 24 patients underwent 
curative neck dissection, whereas 19 patients underwent total parotidectomy sacrificing the 
facial nerve, and 3 patients underwent superficial parotidectomy. In the 3 remaining patients 
the parotid was not surgically treated.  
There were 8 patients with clinical parotid disease and 16 patients with clinical neck disease, 
while there were no patients with a combined clinical finding. Histopathological analysis 
discovered 9 additional histopathologically positive metastases in the parotid gland that were 
clinically unrecognized. Histopathological analysis showed that there was a statistically 
significant higher frequency of neck metastatic disease if the parotid gland is also positive for 
metastases (p=0.022). A positive histopathological finding in the parotid gland is related with 
statistical significance to a higher frequency of neck metastases in all 5 regions (p=0.044), and 
a negative finding is related to a significantly higher frequency of metastatic spread in regions 
II and III (p=0.033). In the cohort with regional metastatic disease, primary lesions localized 
in the temporoauricular, buccal and preauricular areas have a statistically significant higher 
rate of metastatic spread into neck regions IV and V than primary lesions localized in the 
frontonasal, orbital and zygomatic, mental and submental areas (p=0.0299).  
The survival rate calculated by Kaplan-Meier’s method and using the standard AJC staging 
system is displayed in Figure 2. According to the most recent staging system, the N1 stage 
includes patients with a positive clinical finding in the parotid, neck or both. When an 
extended staging system was applied to the same group of patients, a statistically significant 
correlation between survival rate and substages of the PN classification is observed in Figure 
3 (χ²=9.1072, df=2, p=0.0105). Cumulative disease-specific survival was highest in N1 stage, 
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followed by P and N2 stages. Figure 4 shows a significant correlation between survival and P 
stage with cumulative disease-specific survival decreasing significantly with increasing P 
stage (χ²=12.9407, df=3, p=0.0048). 
In Figure 5, a significant correlation between histopathological findings and cumulative 
disease-specific survival was identified, with highest survival in the group that had 
histopathologically verified parotid disease only, and significantly lower survival rates in 
stages N1 and N2 (χ²=12.7359, df=3, p=0.0052). Further data analysis yielded a significant 
correlation between survival rate in patients with isolated neck or parotid metastatic disease 
and those with metastatic disease in both the parotid and neck, as identified in Figure 6 
(χ²=10.2545, df=2, p=0.0059). 
Perineural invasion proved to be a significant negative prognostic factor in the cohort with 
regional metastatic disease (χ²=5.9011, df=1, p=0.0151) (Figure 7). Other analyzed variables 
(primary lesion size, margin status, extracapsular spread) did not yield any significant 
correlations in survival rate data distribution. 
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Discussion 
The majority of head and neck CSCC patients are cured by timely surgical intervention, but 
some develop regional metastatic disease which adversely affects survival. Due to a small 
number of patients with regional metastases, their treatment algorhythms remain 
unstandardized, especially when extent of surgery is concerned. Although some authors 
consider sentinel lymph node biopsy techniques as standard of care, they still have no proven 
survival benefit in the management of head and neck CSCC, and their use remains 
unequivocally investigational.18 It is important to note that metastatic head and neck CSCC 
comprise a heterogeneous group for diagnosing, treating and accurately assessing outcome. 
Due to these factors, the number of patients included in this study is comparable to earlier 
published results. 
The aim of this study is to analyze clinical outcome in a group of patients surgically treated 
for metastatic cutaneous SCC and to document patterns of metastatic spread. We sought to 
confirm current clinical experience that outcome varies with lesion localization, metastatic 
disease and surgical treatment extent. We believe that the present head and neck CSCC 
staging system used in clinical work is inadequate and that an extended staging system of 
regional metastatic disease in the parotid and neck may significantly influence prognosis. The 
second question is whether there is a positive correlation between metastatic disease in the 
parotid gland and the lymphatic nodes in the neck. This information has potential implications 
to treat the clinically negative neck in patients with CSCC involving the parotid. In addition, 
we sought to determine the impact of histopathological parameters, nodal metastasis and 
surgery extent on disease control and patient survival. 
The average age in the regional metastatic disease patient cohort was 73.1 years, with the 
average age in men being 69.8, and 76.4 in women. Male to female ratio was 1:1 (n=24). The 
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median 10-year survival rate for patients with regional metastatic disease was 12.1±9.8%, and 
for the entire patient cohort 45.5±10.2%, which is consistent with published results.8 Analysis 
of the entire population with head and neck CSCC, including patients with regional disease 
(n=103) showed that women are affected significantly later (p<0.0012), probably due to a 
lesser degree of sun exposure and longer life expectancy.19,20 Detailed histopathological 
analysis has identified perineural invasion as a risk factor for nodal metastasis. However, the 
analysis yielded no significant correlations between other tumor characteristics and metastatic 
disease rate, which can likely be attributed to a relatively small sample size, low inadequate 
excision rate and the lack of additional detailed histopatologic data gathered for analysis. 
Other authors have identified lesion size >2 cm, lesion localization, excision margins and 
depth >4 mm as risk factors for lymphatic metastases.6,21 A large study conducted by 
Brantsch et al. with 615 patients designated tumor depth and histological differentiation as 
risk factors for metastatic disease, with 75% of lesions being <2 cm, confirming the opinion 
held by Veness et al, that even small lesions have a significant metastatic potential.8,22 
Lymphatic metastases were identified in 23.3% of the patients, which is slightly higher than 
previously reported rate, ranging from 0.3% to 20.7%. The incidence reflects the practice 
environment of the authors, since the patients referred to our comprehensive cancer center are 
more likely to suffer from aggressive or advanced disease.6,9,12 According to our analysis, the 
number of patients with positive resection margins (6.7%) is consistent with previously 
published studies (6.3% to 15.9%), but shows no correlation to survival or local recurrence 
rates, although patients with T3 stage have a significantly higher rate of positive resection 
margins. Tumor size did not impact survival rates, which is consistent with existing results.11 
No correlation between incomplete excision and regional metastatic disease rates was found, 
most likely due to the consistent treatment protocol used in this study that mandated repeated 
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surgical treatment and adjuvant radiotherapy for all patients with positive resection margins. 
Cutaneous squamous cell carcinoma of the head and neck regions has a low metastatic rate to 
regional lymph nodes (5-10%) and the extraordinarily well developed neck lymphatic system 
poses a strong barrier to further metastatic spread.1,8,13 Bearing that in mind, local and 
regional disease control is essential in improving survival. O’Brien et al have shown the 
importance of the parotid gland in the management and prognosis of CSCC, using a 
modification to current staging systems that includes parotid involvement. This study was 
conducted using O’Brien’s modified PN system.1 The majority of patients with regional 
metastatic disease (16/24) had clinically apparent metastatic disease, 7 patients were 
previously treated by primary tumor excision and had recurrent metastatic disease and one 
patient was primarily treated by radiotherapy. All of the patients with regional metastatic 
disease underwent a comprehensive excision of the primary lesion when present, neck 
dissection dictated by the location of the primary lesion or clinical metastases, and 
postoperative radiotherapy when indicated. Selective neck dissections were performed in the 
majority of cases; most commonly encompassing levels I, II and III (58,3%). The rate of 
recurrence was 11.9%, which confirms the validity of our treatment protocol in comparison to 
literature figures of 21% to 52%.6 
In our study, isolated parotid metastatic disease was found in 8/24 patients, with 16/24 
clinically presenting with isolated neck disease. Histopathologic findings revealed parotid 
involvement in 17/24 patients, and 16/24 had neck lymph node metastases. These results 
differ from data published by Veness et al, that identify the parotid gland as the primary 
clinically positive finding in regional metastatic disease.11 Our study shows that there is a 
significantly higher incidence of clinically positive neck findings with an associated clinically 
negative parotid gland. However, histopathological analysis shows a statistically significant 
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number of false negative parotid clinical findings and a significantly higher rate of 
histopathologically verified regional metastatic disease associated with positive 
histopathological parotid involvement than that of a positive neck associated with a negative 
parotid gland. Although the clinical findings portend the neck as a principal metastatic site, 
the possibility of clinically occult parotid metastatic disease must not be discarded and 
surgery extent should be planned accordingly, as was previously discussed in a study by 
O’Brien et al.11 Previous studies have shown that parotid metastatic involvement leads to a 
poorer prognosis when compared to patients that had regional metastatic disease in the neck 
alone, with the parotid gland free from disease.21,23 Our results indicate that for patients with 
clinically positive parotid involvement and occult neck metastatic disease, an elective neck 
dissection might be beneficial without significant increase in surgery related comorbidity. 
However, the question of elective neck dissection extent remains open for debate. 
Furthermore, the results show that there is a statistically significant association between a 
positive histopathological parotid finding and regional neck metastatic disease. In turn, if the 
parotid is histopathologically negative, metastases are most frequently found in neck regions 
II and III. These results would ration elective neck dissection of neck regions II and III with 
accompanying parotidectomy in high-risk patients, which is supported by published data.24 
The lateral aspect of the head (auriculotemporal) was the most common primary localization 
site in our study. We found that primary lesion localization affects the pattern of metastatic 
distribution. The patients with primary lesions localized in the auriculotemporal, buccal and 
preauricular regions had a significantly higher incidence of metastatic spread into neck 
regions IV and V, which is consistent with a previous study by Veness, Palme and Morgan.11 
This finding supports the idea that primary lesions localized on the lateral side of the face 
have a determined direction of metastatic disease spread. The results speak in favor of 
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extending surgical treatment to a modified radical neck dissection in patients at risk, 
especially if there is clinically evident parotid disease present. The head and neck CSCC that 
have disseminated into the neck and/or parotid gland have a higher incidence of distant 
metastatic disease, are biologically more aggressive and histopathological findings show 
extracapsular spread in 70% of cases, which corresponds to our histopathological analysis 
(12/24 patients had extracapsular spread).25 Better disease control could be achieved through 
encouraging more frequent use of ultrasound and/or MSCT diagnostics in the parotid region 
as a standard clinical practice.26 Local extent of disease is the most important prognostic 
factor for primary head and neck CSCC, and the presence of regional metastases cuts the 
survival rate in half.27 Our study discusses the correlation between clinical and 
histopathological findings and disease outcome using two different staging systems; the 
current AJC staging system, and a recently proposed PN staging system by O’Brien et al. The 
results show that both clinical and histopathological PN staging correlate well with disease 
outcome and survival, whereas the standard N status of the current AJC staging system has no 
significant correlation. Similar results confirm this finding.1,11,12,16,21,23 Clinically evident 
metastatic neck disease staged by the PN system shows a statistically significant correlation 
with survival rate. The N1 group had the best outcome, while N2 had the worst outcome. The 
2-year survival rates for group N1 was 85%, group P had 55% and group N2 had only 17% 
(Figure 3). Since only a small number of authors report a significant correlation (p=0,084) 
between an extended clinical neck and parotid status and survival, the results of this study 
warrant interest and further confirmation in larger patient cohorts.1,11,12,14 Our study has also 
analyzed the relationship between clinical P stage (P1-3) and survival, with a significant 
correlation found (p=0.0048). The group P1 has the best prognosis, followed by P2 and P3 
with the least favorable prognosis, which is consistent with clinical trends reported by 
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O’Brien et al.1 Figure 5 displays that histopathologically positive regional metastatic disease 
adversely affects all PN staging groups with 2-year disease free survival for group P being 
90%, and dropping to 70% and 32% for groups N1 and N2, respectively. This data correspond 
to that previously reported in literature.1,12,13 When comparing the standard AJC N1 staging 
and the extended PN classification N group, a lack of prognostic capability of the AJC staging 
system is evident.  
The results of this study suggest that combining curative parotidectomy and elective neck 
dissection (and vice versa) could be beneficial in high risk patients with CSCC of head and 
neck. In patients with regional metastatic disease, primary lesions localized in 
temporoauricular area, buccal and preauricular areas have a statistically significant higher rate 
of metastatic spread into neck regions IV and V than primary lesions localized in other areas 
of the head and neck. Histopathological analysis showed that there was a statistically 
significant higher frequency of neck metastatic disease if the parotid gland is also positive for 
metastases. Patients with regional metastatic involvement in both the parotid and the neck 
have a significantly worse prognosis than those with parotid involvement alone, regardless of 
primary lesion localization. Regional disease should not only involve metastases of the neck, 
but also metastases in the parotid region, and both should be included in the clinical and 
histological N classification, as is the case with the O’Brien’s PN classification used in our 
study. 
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Table 1. Modified head and neck CSCC staging system (PN classification) as proposed by   
   O'Brien et al.1 
 
P Parotid 
P0  No clinical disease in the parotid 
P1  Metastatic node up to 3 cm in diameter 
P2 Metastatic node > 3 cm and up to 6 cm in diameter or multiple nodes 
P3  Metastatic node > 6 cm in diameter or disease involving  
the facial nerve or skull base 
  
N Neck 
N0  No clinical disease 
N1  Single ipsilateral neck node up to 3 cm in diameter 
N2  Single node > 3 cm in diameter or multiple nodes or 
  contralateral nodes 
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Figure 1. Anatomic regions of the head and neck used in the present study: 1. frontonasal, 2. 
auriculotemporal, 3. mental, submental and submandibular, 4. orbitozygomatic, 5. 
buccal and preauricular region. 
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Figure 2. Patient survival rate displayed using the standard AJCC staging system. Solid line = 
all patients, male and female. 
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Figure 3. Correlation between patient survival rate and clinical N stage using an extended PN 
classification system (p=0.0105). Solid blue line = patients with N1 stage, solid 
orange line = patients with P stage, dashed red line = patients with N2 stage. 
 
 
 
 
 
 
23 
 
Figure 4. Correlation between survival rate and P stage (P1-3) (p=0.0048). Solid blue line = 
patients with N stage, dashed red line = patients with P1 stage, solid orange line = 
patients with P2 stage, dashed green line = patients with P3 stage. 
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Figure 5. Correlation between histopathological PN classification stages and cumulative 
disease-specific survival (p=0.0052). Solid blue line = patients with N1 stage, dashed 
red line = patients with N2 stage, solid orange line = patients with P stage. 
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Figure 6. Correlation between cumulative disease-specific survival and histopathologically 
confirmed parotid and neck metastatic disease (p=0.0059). Solid blue line = patients 
with isolated parotid disease, dashed red line = patients with isolated neck disease, 
solid orange line = patients with both parotid and neck disease. 
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Figure 7. Perineural invasion and survival rate in the cohort with regional metastatic disease 
(p=0.0151) (n=24). Dashed line = positive perineural invasion, solid line = negative  
 
 
 
